Northern Trust Corp Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Northern Trust Corp reduced its stake in Supernus Pharmaceuticals by 1.4%, now holding 706,772 shares worth approximately $23.1 million.
• Multiple hedge funds increased their positions in Supernus Pharmaceuticals, with BNP Paribas Financial Markets boosting its holdings by 248% during the last quarter.
• Brokerages have upgraded Supernus Pharmaceuticals' ratings, with price targets ranging from $40.00 to $46.00, indicating a generally positive outlook for the stock.

Northern Trust Corp reduced its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 706,772 shares of the specialty pharmaceutical company's stock after selling 10,389 shares during the quarter. Northern Trust Corp owned 1.26% of Supernus Pharmaceuticals worth $23,147,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of SUPN. Raiffeisen Bank International AG purchased a new stake in Supernus Pharmaceuticals during the 4th quarter valued at about $25,000. Financial Management Professionals Inc. bought a new stake in Supernus Pharmaceuticals in the first quarter valued at approximately $30,000. Versant Capital Management Inc boosted its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Supernus Pharmaceuticals in the first quarter worth approximately $41,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Supernus Pharmaceuticals in the fourth quarter worth approximately $42,000.

Analysts Set New Price Targets

SUPN has been the subject of several analyst reports. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Piper Sandler raised their target price on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research note on Friday, August 29th. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.00.

Insider Buying and Selling

In related news, Director Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the sale, the director owned 46,307 shares of the company's stock, valued at $1,956,933.82. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Frank Mottola sold 14,000 shares of the company's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $44.51, for a total transaction of $623,140.00. Following the completion of the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $689,726.96. This trade represents a 47.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 179,606 shares of company stock worth $7,617,005 over the last 90 days. Corporate insiders own 8.80% of the company's stock.

Supernus Pharmaceuticals Trading Up 1.2%

Supernus Pharmaceuticals stock traded up $0.53 on Thursday, hitting $45.46. 189,363 shares of the stock traded hands, compared to its average volume of 637,358. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $45.94. The firm has a market cap of $2.55 billion, a P/E ratio of 39.36 and a beta of 0.79. The business's fifty day simple moving average is $37.43 and its 200 day simple moving average is $34.06.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.